This study was designed to investigate the protective effects of the combination of guanosine and 2 organoselenium compounds (ebselen and diphenyl diselenide) against glutamateinduced oxidative stress in different regions of rat brains. Glutamate caused an increase in reactive oxygen species (ROS) generation and a decrease in [ 3 H]-glutamate uptake in striatal, cortical, and hippocampal slices. Guanosine, ebselen, and diphenyl diselenide prevented glutamate-induced ROS production in striatal, cortical and hippocampal slices. The combination of guanosine with organoselenium compounds was more effective against glutamateinduced ROS production than the individual compounds alone. Guanosine prevented [ 3 H]-glutamate uptake inhibition in striatal, cortical, and hippocampal slices. Thus, protection against the harmful effects of glutamate is possibly due to the combination of the antioxidant properties of organoselenium compounds and the stimulatory effect of guanosine on glutamate uptake. In conclusion, the combination of antioxidants and glutamatergic system modulators could be considered a potential therapy against the prooxidant effects of glutamate.
Introduction
The amino acid L-glutamate is the predominant excitatory neurotransmitter in the central nervous system (CNS) of mammals (Gilgun-Sherki et al., 2002; McEntee and Crook, 1993) . After being released in the synaptic cleft, L-glutamate must be removed quickly and efficiently from the extracellular fluid by high-affinity transporters to avoid receptor overstimulation (Danbolt, 2001; Trotti et al., 1998; Walton and Dodd, 2007) . The glutamate transporters in the plasma membranes of both astrocytes and neurons perform this task (Trotti et al., 1998) . These glutamate transporters have an important role in terminating synaptic transmission, as sustained elevation of extracellular glutamate triggers neuronal death through a mechanism termed excitotoxicity (Choi, 1992; Mejia-Toiber et al., 2006) .
Excitotoxicity has been implicated in several neuronal disorders such as epilepsy, ischemia, trauma, amyotrophic lateral sclerosis, Huntington's disease, and Alzheimer's disease (Walton and Dodd, 2007 , and references therein). The mechanisms responsible for the elevation of extracellular glutamate include enhanced release of glutamate and the reduction of glutamate uptake (Gilgun-Sherki et al., 2002) . This process appears to involve sustained elevations of intracellular calcium levels through glutamate transporters, leading to an imbalance of sodium ions across plasma membranes (Gilgun-Sherki et al., 2002) . Excitatory events may stimulate ROS production, and there is evidence that ROS can promote additional glutamate release, generating a vicious amplifying cycle of the neurotoxic cascade (Mailly et al., 1999; Pellegrini-Giampietro et al., 1990) . Indeed, the vulnerability of glutamate transporters to oxidants provides evidence that excitotoxicity and oxidative stress are interrelated and act synergistically to induce neuronal damage (Coyle and Puttfarcken, 1993; Gilgun-Sherki et al., 2002; Trotti et al., 1998) . This concept has general therapeutic implications, as it suggests that using anti-excitotoxic and antioxidant agents in combination may improve neuroprotection (Trotti et al., 1998) .
The redox activity of selenium-containing molecules has been suggested to provide antioxidants of considerable potency Parnham and Graf, 1991) . This has stimulated interest in the synthesis and reactivity of organoselenium compounds, with particular emphasis on their biological properties (Engman et al., 1997; Mugesh et al., 2001; Nogueira et al., 2004) . Of particular importance is that the antioxidant activity of various organoselenium compounds appears to be related, at least in part, to their glutathione peroxidase (GPx)-like activity (Mugesh et al., 2001; Nogueira et al., 2004) .
Ebselen was the first organoselenium compound suggested for hydroperoxide-inactivating therapy in the presence of glutathione . Ebselen has been safely administered in several animal models of brain injuries with pronounced neuroprotective effects (Namura et al., 2001; Takasago et al., 1997) . Based on the encouraging evidence of the neuroprotective effects of ebselen in animal models, clinical trials were conducted with this compound, obtaining modest success (Gilgun-Sherki et al., 2002; Yamaguchi et al., 1998) . Diphenyl diselenide (the simplest of the diaryl diselenides) has been demonstrated to be even more active as a GPx mimic and less toxic to rodents than ebselen (Meotti et al., 2003; Wilson et al., 1989) . In fact, diphenyl diselenide has a protective role in a variety of in vitro and in vivo experimental models associated with the overproduction of free radicals in the brain, liver, and kidney (Burger et al., 2004; Burger et al., 2006; Funchal et al., 2006; Ghisleni et al., 2003 Ghisleni et al., , 2008 Kade et al., 2009; Nogueira et al., 2004; Stangherlin et al., 2008) .
Several studies have demonstrated that the extracellular nucleoside guanosine can exert trophic effects on neural cells, as well as modulate the glutamatergic system (Ciccarelli et al., 2001; Rathbone et al., 1999; Soares et al., 2004) . The mechanism involved in these effects appears to be related to a stimulatory effect on glutamate uptake afforded by guanosine (Frizzo et al., 2001 (Frizzo et al., , 2002 (Frizzo et al., , 2003 Halliwell, 2006; Margaill et al., 2005; Schmidt et al., 2005) . Indeed, guanosine exhibits protective effects in a variety of in vitro and in vivo models of neurotoxicity that involve the overactivation of glutamate receptors (Frizzo et al., 2001 ). In in vitro models, guanosine inhibited glutamate and analogous binding, prevented cell responses to excitatory amino acids, stimulated the uptake of extracellular glutamate by astrocyte cultures and brain slices, and protected brain slices exposed to hypoxia/hypoglycemia (Schmidt et al., 2005 , and references therein). In in vivo models, guanosine protected against seizures induced by glutamatergic agents in rodents (Schmidt et al., 2005) .
Although antioxidants and purine derivatives are very promising compounds for the treatment of CNS disorders, there is no efficient curative treatment that has been proven effective to date. Thus, combinations of treatments may have synergistic effects that are more successful. In the present study, we investigated the protective effects of the combination of guanosine and 2 organoselenium compounds (ebselen and diphenyl diselenide) against glutamate-induced oxidative stress.
Results

Lipid peroxidation
Thiobarbituric acid-reactive substance (TBARS) levels in cortical and hippocampal slices treated with 10 mM glutamate were significantly higher than that observed in control slices (p< 0.05) ( Table 1) . TBARS levels in striatal slices were not affected by treatment with any concentration of glutamate (Table 1) .
Cellular viability
Cellular viability was evaluated by measuring the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to a formazan product by mitochondrial dehydrogenases. Glutamate was not able to decrease mitochondrial viability at any concentration tested in striatal, cortical, and hippocampal slices (data not shown). Lactate dehydrogenase (LDH) release can be an index of cytotoxicity, as it is indicative of disruption of the cellular membrane. Glutamate did not alter LDH release at any concentration tested in striatal, cortical, and hippocampal slices (data not shown).
ROS generation
Glutamate × guanosine
Glutamate significantly increased ROS production (2′,7′-dichlorofluorescin diacetate (DCFH) oxidation) in striatal, cortical, and hippocampal slices at concentrations of 1 and 10 mM (p < 0.05, Fig. 1 ). Guanosine (100 μM) prevented ROS production induced by 1 mM glutamate in striatal, cortical, and hippocampal slices, but could not completely prevent ROS production when it was induced by 10 mM glutamate (p < 0.05, Fig. 1 ). Different concentrations of guanosine were used to prevent DCFH oxidation induced by 1 mM glutamate. Treatment with 100 and 200 μM guanosine blunted glutamate (1 mM)-induced ROS production by striatal slices (p > 0.05, Fig. 2A ). In cortical and hippocampal slices, guanosine treatment prevented ROS production at concentrations of 10 and 20 μM, respectively (p < 0.05, Figs. 2B, C). Cortical and hippocampal slices were more sensitive to guanosine than striatal slices were.
Glutamate × organoselenium compounds
At low concentrations, diphenyl diselenide and ebselen significantly prevented glutamate (1 mM)-induced ROS generation in striatal, cortical, and hippocampal slices. Treatment with diphenyl diselenide decreased glutamate (1 mM)-induced ROS production to the control levels at concentrations of 0.5, 0.5, and 10 μM in striatal, cortical, and hippocampal slices, respectively (p< 0.05, Fig. 3 ). Ebselen prevented glutamate (1 mM)-induced ROS production at concentrations of 0.5, 1, and 5 μM in striatal, cortical, and hippocampal slices, respectively (p < 0.05, Fig. 4 ).
Glutamate × combined treatment (guanosine + organoselenium compounds)
Considering that organoselenium compounds act as antioxidants and guanosine could affect glutamate uptake, the use of both in combination could better protect against glutamate induced-ROS generation, as they could act via different mechanisms. To test this hypothesis, we investigated whether noneffective concentrations of each compound in combination could exert protective effects against glutamate induced-ROS generation to avoid any possible toxic effect caused by high concentrations of these compounds. Indeed, the combination of 10 μM guanosine and 1 μM diphenyl diselenide was more effective in preventing glutamate-induced ROS generation in striatal, cortical, and hippocampal slices than the individual compounds alone (p < 0.05, Fig. 5 ). The combination of 100 μM guanosine with diphenyl diselenide (1 μM) was also effective in protecting against glutamate-induced ROS production in striatal, cortical, and hippocampal slices, although this protection was not different from that exerted by guanosine (100 μM) and diphenyl diselenide (1 μM) alone (p< 0.05, Fig. 5 ).
The combination of ebselen (1 μM) and guanosine (10 μM) was better than the individual compounds alone in protecting against ROS generation induced by glutamate (1 mM) in striatal, cortical, and hippocampal slices (p< 0.05, Fig. 6 ). Treatment of striatal, cortical, and hippocampal slices with the combination of guanosine (100 μM) and ebselen (1 μM) significantly prevented glutamate (1 mM)-induced ROS production, although these changes were indistinguishable from those caused by either compound [guanosine (100 μM) and ebselen (1 μM)] alone (p< 0.05, Fig. 6 ).
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Discussion
The overstimulation of glutamate receptors triggers a sequence of cellular events that includes oxidative stress and contributes to the pathophysiology of a number of brain injuries (Danbolt, 2001; Mejia-Toiber et al., 2006; Walton and Dodd, 2007) . In this study, glutamate augmented ROS production as well as decreased its uptake in striatal, cortical, and hippocampal slices from rats, characterizing the primary events of harmful glutamatergic overstimulation. Glutamate induced an increase in TBARS levels in cortical and hippocampal slices only at the highest concentration tested (10 mM); however, the concentration of 1 mM used throughout the study did not induce changes in the TBARS levels. Here, we would like to call attention to the fact that the TBARS assay is only a global test for assessing lipid peroxidation because thiobarbituric acid (TBA) is nonspecific for malondialdehyde (MDA) and can react with nonlipid-related materials and fatty peroxide-derived decomposition products other than MDA (Janero, 1990) . In this manner, utilization of the TBARS assay in lipid peroxidation studies requires caution regarding the interpretation of its results. Glutamate did not induce a loss of viability in the assays performed in this study (MTT reduction and LDH release), indicating that the slices were viable during all experiments despite the increase in ROS levels and the impairment of glutamate uptake. In addition, we demonstrated that guanosine, ebselen, and diphenyl diselenide protected striatal, cortical, and hippocampal slices from rats from the ROS production evoked by glutamate. An oxidative stress condition and impairment of glutamate transport have been observed in parallel in several brain pathologies leading to acute or chronic neurodegeneration (Trotti et al., 1998) . Amyotrophic lateral sclerosis, Alzheimer's disease, and ischemic and traumatic injuries are examples of brain pathologies in which alterations in glutamate transport and oxidative stress are involved. The toxic pathways by which exposure to excess glutamate can lead to aberrant ROS formation include Ca 2 + -dependent activation of nitric oxide (NO) synthase, phospholipase A 2 , and xanthine oxidase (Trotti et al., 1998) . In this manner, antioxidants are certainly a promising therapeutic class for the treatment of neurodegenerative diseases (Halliwell, 2006; Margaill et al., 2005) .
Organoselenium compounds have been proposed as potential therapeutic agents against the formation of free radicals and the deleterious actions of ROS secondary to a variety of neuronal injuries (Centuriao et al., 2005; Nogueira et al., 2004; Posser et al., 2008; Zhao and Holmgren, 2002) . In fact, the neuroprotective effects of ebselen and diphenyl diselenide have been attributed to the antioxidant properties of these compounds (Rossato et al., 2002; Warren, 2002) . In addition, it has been reported that low selenium concentrations in the elderly were significantly associated with senility and cognitive decline (Berr et al., 2000) . In view of these findings, the protective effects of both compounds could be related to their ability to prevent the first signs of glutamate neurotoxicity, such as oxidative stress.
In this study, guanosine was able to prevent the increase in ROS generation induced by glutamate in striatal, cortical, and hippocampal slices. These results again demonstrate the relationship between increased extracellular glutamate and increased ROS production, as guanosine also protected against the inhibition of glutamate uptake in all brain regions. In fact, guanine-based purines such as guanosine are well-known modulators of the glutamatergic system, and their neuroprotective effects have been demonstrated in several studies (Ciccarelli et al., 2001; Frizzo et al., 2001 Frizzo et al., , 2002 Frizzo et al., , 2003 Rathbone et al., 1999; Schmidt et al., 2005) . Therefore, the protective effects of guanosine observed here could be related with its ability to reduce extracellular glutamate by activating glutamate uptake into astrocytes (Frizzo et al., 2002; Soares et al., 2004) , subsequently preventing ROS production.
Although antioxidants and purine derivatives have proven efficiency in counteracting the toxic effects of glutamate, there are no effective therapeutics for CNS injuries associated with the overactivation of glutamate receptors to date. Thus, the combination of antioxidants and purine derivatives could be more interesting than each compound being used separately for 2 reasons. Firstly, it would afford protection via different mechanisms, as the antioxidant would act by attacking the ROS, whereas guanosine would act by modulating the glutamatergic system. Secondly, the combination of drugs allows the use of lower concentrations of each compound. This fact is of great importance, as one problem with using high doses of antioxidants is that they can become toxic. Studies have reported that ebselen at high doses impaired glutamate transmission as part of its toxic effects, and low doses prevent glutamate-mediated neuronal death associated with its antioxidant and/or antiinflammatory properties Porciuncula et al., 2001 Porciuncula et al., , 2003 . In the same manner, diphenyl diselenide has been demonstrated to exhibit neuroprotective, antiinflammatory, and antinociceptive activity (Meotti et al., 2004; Nogueira et al., 2003 Nogueira et al., , 2004 , although exposure to high doses of diphenyl diselenide induces seizure and death in rat pups and alters glutamatergic homeostasis (uptake and binding) in vitro and in vivo (Nogueira et al., 2001; Prigol et al., 2007) . Thus, the combination of therapies might decrease the dosages for each agent and consequently reduce the occurrence of adverse effects (Margaill et al., 2005) .
In view of this, the main objective of this study was to investigate whether the combined use of guanosine and organoselenium compounds could be more effective against glutamateinduced oxidative stress than the individual compounds. Indeed, the combination of guanosine and organoselenium compounds prevented glutamate-triggered ROS production in striatal, cortical, and hippocampal slices. These results corroborate the idea that the combined treatment is more effective than the isolated use of each compound. Additionally, a recent study demonstrated that organoselenium compounds used in combination with guanosine can protect rat brain cortical slices against methylmercury-induced ROS production related to glutamatergic system disturbances (Roos et al., 2009 ).
Another point that should be noted is the different responses of the brain regions to glutamate, guanosine, and organoselenium compounds. According to our results, cortical and hippocampal slices were more sensitive to the deleterious effects of glutamate than striatal slices were, as observed by the ROS and TBARS production induced by 10 mM glutamate. In addition, the inhibition of glutamate uptake was more pronounced in cortical and hippocampal slices. One explanation for these differences could be the different concentrations and distribution of glutamate receptors and transporters among the brain regions (Erecinska and Silver, 1996; Maiti et al., 2006) . Glutamatergic synapses are more abundant in the cortex and hippocampus than in the striatum (Lehre et al., 1995) . These findings could explain the lower susceptibility of striatal slices to glutamate compared to cortical and hippocampal slices.
Moreover, cortical and hippocampal slices were more sensitive to guanosine than striatal slices regarding glutamateinduced ROS formation, which could also be explained by the higher glutamatergic activity of these regions. However, the effects of guanosine on glutamate uptake did not differ among the brain regions. Therefore, other mechanisms could also be involved in the ability of guanosine to decrease ROS production. In addition to the stimulation of glutamate uptake, the decrease in glutamate binding and the scavenging of hydroxyl radicals induced by guanosine may also contribute to the protection and to the different sensitivity observed among the brain regions (Gudkov et al., 2006; Rubin et al., 1997) .
The response of each region to the effect of the organoselenium compounds on ROS production varied according to the concentrations used. The concentrations of organoselenium compounds necessary to counteract ROS production were lower in striatal and cortical slices than in the hippocampal slices. In addition, the combined treatments were less effective in the striatal slices than in hippocampal and cortical slices, which could also be a consequence of the differences in the glutamatergic activity among these brain regions. Although we attribute the neuroprotection afforded by the organoselenium compounds to its antioxidant properties, we cannot rule out the involvement of other mechanisms.
The discovery and development of potent antioxidant agents has been one of the most promising approaches in the search for treatments for CNS injury (Gilgun-Sherki et al., 2002) . Although some of the antioxidants exhibited efficacy in animal models, most of them did not exhibit beneficial effects in clinical trials performed to date (Gilgun-Sherki et al., 2002) . The combination of antioxidants and substances capable of modulating glutamatergic activity would be more effective than the compounds alone because this combination could diminish oxidative stress generated via overactivation of NMDA receptors and still could diminish excess glutamate in synaptic clefts (Salom et al., 2004) . Our findings supported this idea and demonstrated that organoselenium compounds in combination with guanosine are promising tools against glutamate-induced oxidative injury in CNS disorders. Furthermore, additional studies are necessary to determine the efficacy of the combination of organoselenium compounds with guanosine in reducing the prooxidative effects of glutamate in an in vivo model.
4.
Experimental procedure
Materials
[ 3 H]-glutamic acid was purchased from Amersham Biosciences (Amersham, Bucks, UK). Guanosine, TBA, and MTT were Fig. 6 -Effect of the combination of guanosine (Gua) and ebselen (Ebs) on glutamate (Glut)-induced ROS production in striatal (A), cortical (B), and hippocampal (C) slices from rats. Data are expressed as the mean ± S.E.M., n = 6. Experiments were performed in duplicate. Bars with different letters are significantly different (p < 0.05) from each other. Asterisk indicates significant differences from the control (p < 0.05).
obtained from Sigma Aldrich (St Louis, MO, USA). DCFH was purchased from Molecular Probes (Eugene, OR, USA). Ebselen was synthesized with the method described by Engman and Hallberg (1989) . Diphenyl diselenide was synthesized with the method described by Paulmier (1986) . Solutions of organochalcogens were prepared freshly in dimethylsulfoxide (DMSO), and the final concentration of DMSO in the experiments was 2%. All other chemicals were of analytical grade and purchased from local commercial suppliers.
Animals
Male adult Wistar rats (250-350 g) from our own breeding colony were kept in cages of 4 animals each. They were placed in a room with controlled temperature (22 ± 3°C) on a 12-h light/dark cycle with lights on at 7:00 a.m. and continuous access to food and water. Our institutional protocols on animal experimentation, which were designed to minimize suffering and limit the number of animals sacrificed, were followed throughout the study. All experiments were conducted in accordance with the Committee on Care and Use of Experimental Animal Resources of the Federal University of Santa Maria, Brazil.
Slice preparation
Animals were sacrificed by decapitation. The brain was quickly removed, placed on ice, and then dissected into 3 specific regions: the cortex, the hippocampus, and the striatum. Slices (0.4-mm thick) of the brain regions were rapidly prepared using a McIlwain Tissue Chopper and then placed in ice-cold artificial cerebrospinal fluid (ACSF) containing 120 mM NaCl, 5 mM KCl, 1.3 mM MgCl 2 , 1.5 mM CaCl 2 , 1.25 mM NaH 2 PO 4 , 35 mM NaHCO 3 , and 10 mM D-glucose. The buffer was bubbled with 95% O 2 and 5% CO 2 up to pH 7.4 throughout the experiments.
Lipid peroxidation assay
Lipid peroxidation in the cortex, hippocampus, and striatum was evaluated by the TBARS method according to Rios and Santamaria (1991) . The slices (5) were preincubated with L-glutamate (0.01, 0.1, 1, and 10 mM) for 2 h in oxygenated ACSF. For the TBARS assay, the slices were homogenized in 500 μL of icecold ACSF, and 1 mL of the TBA reagent (15% trichloroacetic acid, 0.375% TBA, and 2.5% v/v HCl) was added. After 30 min of incubation, samples were centrifuged (3000×g, 15 min), and the TBARS levels were measured at 532 nm in the supernatant. The final amounts of TBARS, mostly MDA, were calculated by interpolation of values in an MDA standard curve and corrected by the content of protein per sample. The results were calculated as nmol of TBARS/mg of protein and expressed as percent of controls.
Cellular viability assay
Cellular viability in the cortex, hippocampus, and striatum was quantified by measuring the reduction of MTT to a dark violet formazan product by mitochondrial dehydrogenases (Mosmann, 1983) . The slices (2) were incubated with L-glutamate (0.01, 0.1, 1, and 10 mM) for 2 h in oxygenated ACSF. After incubation, the slices were washed twice with 1 mL of ACSF. The MTT reduction assays were performed in plates containing 1 mL of ACSF, and the reaction was started by adding 0.5 mg/mL MTT. After 1 h of incubation at 37°C, the medium was removed, and the precipitated formazan in the slices was solubilized in DMSO. The rate of MTT reduction was measured spectrophotometrically at 570 nm. The results 
4.6.
LDH release assay LDH release, an index of cell disruption, was assessed in slices of the cortex, hippocampus, and striatum. The slices (2) were incubated with L-glutamate (0.01, 0.1, 1, and 10 mM) by 2 h in oxygenated ACSF. After this period, the total incubation medium of the slices (1 mL) was removed and mixed with reaction medium containing 100 mM glycine-KOH buffer (pH 10), 50 mM lactate, and 1 mM NAD + . The enzyme activity was measured by determining the amount of NADH formed at room temperature at 340 nm (Pereira et al., 1991) . Total LDH activity was determined by the same procedure described above after adding a final concentration of 10% Triton X-100 and disrupting the slice by homogenization. LDH leakage was estimated as the ratio between the LDH activity in the incubation medium and that of the whole slice content. The results were expressed as percent of LDH activity with respect to control values.
Estimation of ROS generation
Generation of ROS was estimated with the fluorescent probe DCFH by the method described by Ali et al. (1992) . Slices (2) of the cortex, hippocampus, and striatum were preincubated with 100 μM guanosine in oxygenated ACSF for 15 min at 37°C. Then, L-glutamate (0.01, 0.1, 1, and 10 mM) was added to the slices and incubated for another 2 h in order to create a dose-response curve of DCFH oxidation. The glutamate concentration of 1 mM was used to perform the other experiments with guanosine and organoselenium compounds because it was the lowest concentration of glutamate that significantly induced ROS generation (DCFH oxidation), which is supported by other studies (Kannurpatti, et al., 2004; Molz, et al., 2011) . Then, we performed dose-response curve of DCFH oxidation with L-glutamate (1 mM) versus guanosine (0.5-200 μM), diphenyl diselenide (0.05-100 μM), and ebselen (0.01-100 μM). To study the effect of the combination of guanosine and organoselenium compounds, the concentrations of 10 and 100 μM were chosen for guanosine, and 1 μM was chosen for diphenyl diselenide and ebselen. For the DCFH oxidation assay, the slices were homogenized in 2.5 mL of saline solution (0.9% NaCl). Aliquots of 2.5 mL were incubated in the presence of DCFH (5 μM) at 37°C for 1 h. Fluorescence was measured using excitation and emission wavelengths of 488 and 522 nm, respectively. A calibration curve was established with standard DCF. ROS levels were expressed as percent of control as follows: (F− Fo) / Fo⁎ 100, where F is the fluorescence intensity of the control slices and Fo is the fluorescence intensity of the slices treated with glutamate, guanosine, and/or organoselenium compounds. The data with organoselenium compounds alone was omitted because they did not exert any effect per se on the fluorescence measurements (DCFH fluorescence).
[ 3 H]-glutamate uptake assay
For the glutamate uptake measurement, slices (2) of the cortex, hippocampus, and striatum were preincubated with and without 10 and 100 μM guanosine in oxygenated ACSF during 15 min at 37°C. Then, 1 mM L-glutamate was added to the slices and incubated for another 2 h. At the end of the incubation period, the slices were washed twice with ACSF and adjusted to pH 7.2. Glutamate uptake was performed according to Frizzo et al. (2002) with some modifications. Briefly, uptake was performed at 35°C by adding 100 μM unlabeled L-glutamate and 1 μM (0.33 μCi/mL) [ 3 H]-glutamate. The reaction was stopped after 7 (cortex), 5 (hippocampus), or 3 (striatum) min by washing twice with 1 mL of cold ACSF, immediately followed by the addition of 0.5 N NaOH, which was kept overnight. Sodiumindependent uptake was determined using choline chloride instead of sodium chloride, which was subtracted from the total uptake to obtain the sodium-dependent uptake. Incorporated radioactivity was determined with a Packard scintillator (TRI CARB 2100 TR-PerkinElmer, Waltham, MA, USA).
Protein measurement
Protein concentrations were assayed by the method of Lowry et al. (1951) with bovine serum albumin as the standard.
Statistical analysis
Data were analyzed statistically by 1-way ANOVA, followed by Duncan's post-hoc tests. The results were considered statistically significant when p<0.05.
